Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash & Current Investments: 2023-2024

Historic Cash & Current Investments for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $19.6 million.

  • BioLineRx's Cash & Current Investments fell 14.45% to $28.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $103.3 million, marking a year-over-year decrease of 28.02%. This contributed to the annual value of $19.6 million for FY2024, which is 54.50% down from last year.
  • According to the latest figures from FY2024, BioLineRx's Cash & Current Investments is $19.6 million, which was down 54.50% from $43.0 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Cash & Current Investments ranged from a high of $43.0 million in FY2023 and a low of $19.6 million during FY2024.
  • Moreover, its 2-year median value for Cash & Current Investments was $31.3 million (2023), whereas its average is $31.3 million.
  • Data for BioLineRx's Cash & Current Investments shows a maximum YoY tumbled of 54.50% (in 2024) over the last 5 years.
  • BioLineRx's Cash & Current Investments (Yearly) stood at $43.0 million in 2023, then slumped by 54.50% to $19.6 million in 2024.